ライフサイエンスコーパス: exacerbation

1 itation, symptoms, and frequency of previous exacerbations).

2 tcome was any protocol-defined severe asthma exacerbation.

3 time to first protocol-defined severe asthma exacerbation.

4 l GWG (P < .001) compared with women without exacerbation.

5 with viruses to increase the risk of asthma exacerbation.

6 p were also associated with those who had an exacerbation.

7 onse that involves eosinophils underlies the exacerbation.

8 acute chronic obstructive pulmonary disease exacerbation.

9 ed at curbing allergic lung inflammation and exacerbation.

10 tic that is usually not seen during an acute exacerbation.

11 nd/or MCP-1 in the mechanisms of RSV-induced exacerbation.

12 failure (25-15%) in severe hypercapnic COPD exacerbations.

13 ne FEV1 but was influenced by the history of exacerbations.

14 mmunoinflammatory cascade that drives asthma exacerbations.

15 eased susceptibility to virus-induced asthma exacerbations.

16 increased predictive value for future severe exacerbations.

17 h muco-obstructive lung disease to bacterial exacerbations.

18 ent the most common cause of allergic asthma exacerbations.

19 patients required in a drug trial for severe exacerbations.

20 at maintain asthma control and reduce asthma exacerbations.

21 ct infections synergistically promote asthma exacerbations.

22 ted nucleotide metabolism associated with CF exacerbations.

23 predictive value of clinical covariates for exacerbations.

24 OPD, FEV1 of less than 50%, and a history of exacerbations.

25 biomarkers to clinical variables to predict exacerbations.

26 more effective strategies to prevent asthma exacerbations.

27 allergy further increases the risk of asthma exacerbations.

28 was used to identify risk factors for asthma exacerbations.

29 il thresholds and a history of more frequent exacerbations.

30 allergic sensitization, severity, and recent exacerbations.

31 e of the main causes of virus-induced asthma exacerbations.

32 e before and after rhinovirus-induced asthma exacerbations.

33 noviruses (HRVs) commonly precipitate asthma exacerbations.

34 ceptor alpha reduces the frequency of asthma exacerbations.

35 eby MCs may contribute to HRV-induced asthma exacerbations.

36 als for the CompEx versus episodes of severe exacerbations.

37 ts with COPD, during both stable disease and exacerbations.

38 gest the important role of allergy in asthma exacerbations.

39 herapeutic approach for virus-induced asthma exacerbations.

40 response to antibiotic therapy for pulmonary exacerbations.

41 secondary to allergen- and pathogen-induced exacerbations.

42 om severity may all contribute to decreasing exacerbations.

43 rleukin-8 concentrations, than were no acute exacerbations.

44 ma symptom days (90.7 vs 41.2, P = .004) and exacerbations (1.4 vs 0.6, P = .006), while similar prot

45 ma symptom days (90.7 vs 53.2, P = .020) and exacerbations (1.4 vs 0.8, P = .009) thanNW children did

46 zard ratio (HR) was 5.0 (95% CI 2.8-8.9) for exacerbations, 1.7 (1.3-2.2) for pneumonia, 0.7 (0.2-3.0

47 Corresponding HRs were 15.5 (11.0-21.8) for exacerbations, 2.8 (2.4-3.3) for pneumonia, 4.3 (2.8-6.7

48 cebo group had attended the hospital with an exacerbation (36 [29.3%] of 123 vs. 49 [41.5%] of 118; P

49 acerbations per year than in those with zero exacerbations (4194+/-878 vs. 2458+/-113 mug per millili

50 ls), rates of hospital attendance for asthma exacerbations (-9.83% [-16.62 to -3.04]; five studies, 6

51 ors of future exacerbations include previous exacerbation, airflow obstruction, poor overall health,

52 salmeterol/fluticasone for the prevention of exacerbations (all severities, or moderate or severe) in

53 the role of ILC2s in asthma persistence and exacerbation among human subjects, and thus, regulation

54 Time to first protocol-defined exacerbation analysis revealed a significantly different

55 10) were performed at the time of pulmonary exacerbation and after antibiotic therapy.

56 otified if a participant met criteria for an exacerbation and contacted participants to determine if

57 Stress is a ubiquitous risk factor for the exacerbation and development of affective disorders incl

58 complicated due to risk for maternal disease exacerbation and potential for fetal and neonatal compli

59 Secondary outcomes included time to first exacerbation and subsequent exacerbation, quality of lif

60 e significantly associated with a history of exacerbation and with a future exacerbation, but there w

61 jects in the SARP-3 cohort, 294 (41%) had no exacerbations and 173 (24%) were exacerbation prone in t

62 evere COPD and associated with more frequent exacerbations and a loss of microbiota diversity.

63 ) are more frequent than those for acute IPF exacerbations and are associated with poor outcomes.

64 itulates all major features of severe asthma exacerbations and can serve to discern driving mechanism

65 ring periods of disease stability and during exacerbations and compared with clinical measures of dis

66 s pDC numbers were markedly increased during exacerbations and correlated with the severity of inflam

67 uration and, with standardised collection of exacerbations and diary card variables, were used to con

68 ed to understand year to year variability in exacerbations and factors associated with consistent exa

69 as been shown to significantly reduce asthma exacerbations and improve lung function for patients wit

70 y be a source of stress-induced inflammatory exacerbations and pain.

71 We obtained information on exacerbations and pneumonia from the National Danish Pat

72 , asymptomatic COPD had an increased risk of exacerbations and pneumonia.

73 A strong association exists between asthma exacerbations and respiratory viral infections, and inte

74 articularly successful in controlling asthma exacerbations and suggest ways in which future clinical

75 2 months and decreased the numbers of severe exacerbations and the dose of oral corticosteroids.

76 bations (individuals who had both years with exacerbations and years without during the 3 years of fo

77 We defined exacerbations (and acute respiratory events in those wit

78 uitment, increased eosinophil number, recent exacerbation, and higher treatment step were also associ

79 rol ligands for EBI2 are increased in asthma exacerbation, and if or how they promote Eos pulmonary m

80 sis, asthma phenotypes, severe asthma, acute exacerbations, and clinical management of disease in adu

81 reterm birth, hospital attendance for asthma exacerbations, and hospital attendance for respiratory t

82 rapidly depletes eosinophils, reduces asthma exacerbations, and improves lung function for patients w

83 roup with more severe disease, more frequent exacerbations, and increased emphysema by QCT.

84 ent association was found with dyspnea, QoL, exacerbations, and mortality.

85 comorbid conditions, allergic sensitization, exacerbations, and very poorly controlled asthma, includ

86 ed on Asthma Control Test scores, numbers of exacerbations, and visits to the emergency department (a

87 Exacerbations are associated with accelerated lung funct

88 erefore, trials that assess drug efficacy on exacerbations are done late in clinical development prog

89 We defined total exacerbations as subject-reported worsening in respirato

90 rticosteroids and/or antibiotics, and severe exacerbations as those leading to hospitalizations or em

91 zema (AE) is colonization by S. aureus, with exacerbations associated with an increased bacterial bur

92 pes were assessed as predictors of number of exacerbations, asthma severity, and airway lability.

93 Disease exacerbation at thermoneutrality was conserved across mu

94 ely to have respiratory infections and acute exacerbations at baseline or to develop them subsequentl

95 nificantly associated with the occurrence of exacerbations but were not robust between cohorts and ad

96 th uncontrolled severe asthma with increased exacerbations but with normal lung function.

97 a history of exacerbation and with a future exacerbation, but there was minimal replication between

98 costeroid monotherapy in controlling disease exacerbations, but their effect on airway remodelling an

99 can be stratified into prevention of disease exacerbations by using proactive approaches (with either

100 Disease severity (dyspnea, QoL, exacerbations, comorbidities) and prognosis (mortality)

101 t step were associated with those who had an exacerbation compared with those who did not.

102 mmon adverse events were infective pulmonary exacerbations, cough, increased sputum, and haemoptysis.

103 omial model was used to assess predictors of exacerbation count during follow-up in all patients with

104 iary events) that, when combined with severe exacerbations, create a composite outcome (CompEx).

105 bability of having an allergic rhinitis (AR) exacerbation day (from 11% [placebo] to 5% [SQ house dus

106 49%) of 1105 patients had at least one acute exacerbation during the 3 years of follow-up, whereas 56

107 yzed to characterize those who had an asthma exacerbation during the Preventative Omalizumab or Step-

108 We assessed retrospective exacerbations during the 12 months before enrollment and

109 (7%) of 1105 patients had at least one acute exacerbation each year, whereas only 23 (2%) had two or

110 end point was the annualized rate of asthma exacerbations (events per patient-year) at week 52.

111 oesophageal reflux were also associated with exacerbation frequency (1.7 [1.4-2.1] and 1.6 [1.3-2.0])

112 socioeconomic status) did not associate with exacerbation frequency in SARP-3; bronchodilator respons

113 RATIONALE: Reducing asthma exacerbation frequency is an important criterion for app

114 onists (LAMAs) provide greater reductions in exacerbation frequency than either their monocomponents

115 h a severe COPD phenotype, including greater exacerbation frequency, and whether blood eosinophils ar

116 We classified patients according to yearly exacerbation frequency: no exacerbations in any year; on

117 ith higher baseline symptom burden, previous exacerbations, greater evidence of small airway abnormal

118 In logistic regression, consistent acute exacerbations (>/=1 event per year for 3 years) were ass

119 than usual care arm subjects (time to first exacerbation hazard ratio, 1.45; 95% confidence interval

120 chronic obstructive pulmonary disease (COPD) exacerbations, helium/oxygen (heliox) reduces the work o

121 ent baseline blood eosinophil thresholds and exacerbation histories.

122 flammation during a rhinovirus-induced acute exacerbation; however, only anti-IL-33 boosted antiviral

123 ed mental status and late multiple sclerosis exacerbation in another patient.

124 ct those children unlikely to have an asthma exacerbation in both groups.

125 A higher saEPI was associated with an exacerbation in both the GBT alone (P < .001; area under

126 frequency: no exacerbations in any year; one exacerbation in every year during 3 years of follow-up;

127 ses were patients with COPD and at least one exacerbation in the past year or FEV1 less than 60% of p

128 or with mild COPD (FEV1 >/=60% predicted, no exacerbation in the past year).

129 r or FEV1 less than 60% of predicted without exacerbation in the past year.

130 an 50%, at least one moderate-to-severe COPD exacerbation in the previous 12 months, and a COPD Asses

131 eight (25.8%) patients experienced an asthma exacerbation in the prior 3 months requiring hospital at

132 ardless of whether subjects had a history of exacerbation in the year before the study or an FEV1 <60

133 cording to yearly exacerbation frequency: no exacerbations in any year; one exacerbation in every yea

134 g bronchodilators to treat asthma and wheeze exacerbations in children 0-18 years presenting to the E

135 to detect responses to therapy for pulmonary exacerbations in children with CF.

136 able bedding and its impact on severe asthma exacerbations in children.

137 e enrollment and then documented prospective exacerbations in each cohort.

138 , whereas only 23 (2%) had two or more acute exacerbations in each year.

139 th asthma inception in early life and asthma exacerbations in older children and adults.

140 corticosteroids have been shown to decrease exacerbations in patients with moderate to severe chroni

141 olizumab, an IL-5-blocking antibody, reduces exacerbations in patients with severe eosinophilic asthm

142 duce the frequency of clinically significant exacerbations in patients with severe eosinophilic asthm

143 Whether exacerbations in subjects with mild COPD or similar acut

144 inner-city children with and without asthma exacerbations in the fall period treated with guidelines

145 , the mean annual rate of moderate or severe exacerbations in the modified intention-to-treat populat

146 clinical risk score composed of >/=2 severe exacerbations in the past year (+2 points), history of n

147 Patients were classified by their number of exacerbations in the past year: none, few (one to two),

148 tion 50/500 mug in patients with one or more exacerbations in the preceding year.

149 n this longitudinal, prospective analysis of exacerbations in the Subpopulations and Intermediate Out

150 This was an analysis of exacerbations in the SUMMIT (Study to Understand Mortali

151 In addition to symptoms and history of exacerbations in the year before study enrolment, we ide

152 Published predictors of future exacerbations include previous exacerbation, airflow obs

153 This exacerbation includes increase of IL-5, IL-13, eotaxin a

154 novel biomarkers associated with consistent exacerbations, including CT-defined small airway abnorma

155 rs of follow-up; and those with inconsistent exacerbations (individuals who had both years with exace

156 Assessing future risk of exacerbations is an important component of asthma manage

157 budesonide versus placebo for severe asthma exacerbations, lung function, and asthma symptom control

158 During exacerbations, MMP-1 activity increased and was associat

159 The early intervention arm subjects detected exacerbations more frequently than usual care arm subjec

160 markers of disease severity, and with future exacerbations, mortality and lung function decline over

161 il count is associated with the risk of COPD exacerbations, mortality, decline in FEV1, and response

162 trajectory and persistently frequent severe exacerbations need to be identified early to guide treat

163 uality is misleading as oxidative stress and exacerbation occur when oxidant foods (e.g. fava beans)

164 associated with an increased risk of asthma exacerbation (odds ratio, 9.35; 95% CI, 6.39-13.68; P <

165 cells into the circulation not only leads to exacerbation of AD through T-cell skin infiltration but

166 ll-like receptor (TLR) 2, TLR4 and MyD88, in exacerbation of allergen-induced lung eosinophilia cause

167 nt with a DNA-demethylating agent alleviated exacerbation of allergic airway inflammation.

168 sly established a mouse model of RSV-induced exacerbation of allergic airways disease, which mimics h

169 elop therapeutics to treat the virus-induced exacerbation of asthma.

170 cytes are key players in the development and exacerbation of atherosclerosis, which prompts the quest

171 tes have been implicated in the etiology and exacerbation of atopic dermatitis.

172 ads to an increase in the number of OCs, and exacerbation of bone damage.

173 h sham-operated controls, CKD mice exhibited exacerbation of cardiac dysfunction and lung inflammatio

174 ction is associated with the development and exacerbation of childhood asthma.

175 tent, and reproducible mouse model of severe exacerbation of chronic allergic asthma.

176 Stress is associated with the exacerbation of clinical symptoms and the induction of r

177 d the noradrenergic system to demonstrate an exacerbation of cognitive deficits, neuroinflammation, n

178 th persistent hypercapnia following an acute exacerbation of COPD, adding home noninvasive ventilatio

179 cells or conditioning therapy, resulting in exacerbation of GVHD.

180 IL-4 exacerbation of histamine-induced hypovolemic shock in m

181 losteric modulation of mGluR5 results in the exacerbation of hyperactivity and epileptic phenotypes.

182 SC by adoptive transfer caused a significant exacerbation of infection in S. aureus-infected mice.

183 The most serious side effects were exacerbation of left ventricular failure in patients wit

184 polysaccharide may be a strong candidate for exacerbation of murine lung eosinophilia.

185 lleviation of inflammatory processes and the exacerbation of neurodegenerative processes, androgens m

186 ive mitochondrial dysfunction and consequent exacerbation of oxidative stress.

187 vivors for therapy-related complications and exacerbation of preexisting conditions are important and

188 deficiency (Il17ra(-/-) ) resulted in severe exacerbation of skin inflammation.

189 ission to a psychiatric inpatient unit after exacerbation of symptoms within 2 years of first present

190 t of male reproductive organ development and exacerbation of the C (+/+)/Tia1 (-/-) testis transcript

191 s and IL-17C+KO mouse skin, and confirmed an exacerbation of the inflammatory signature in IL-17C+KO

192 sDNA) following rhinovirus infection and the exacerbation of type-2 allergic inflammation in humans.

193 ify pregnancy-related risk factors for acute exacerbations of asthma during pregnancy.

194 ng otitis media, chronic rhinosinusitis, and exacerbations of both cystic fibrosis and chronic obstru

195 Bacterial respiratory tract infections and exacerbations of chronic lung diseases are commonly caus

196 Exacerbations of COPD were an additional predefined endp

197 cess deaths from ischaemic heart disease and exacerbations of COPD.

198 ebo-controlled trials in patients with acute exacerbations of schizophrenia, and they investigate whi

199 vere lower respiratory tract infections, and exacerbations of underlying disease; 0.2%-11.5% of hospi

200 blished clinical features were predictive of exacerbations, of the blood biomarkers only decorin and

201 models to fit FEV1 decline based on reported exacerbations or acute respiratory events.

202 d with placebo, irrespective of a history of exacerbations or baseline FEV1.

203 ot a reliable biomarker for COPD severity or exacerbations, or for sputum eosinophils.

204 Among patients who had any acute exacerbation over 3 years, very few repeatedly had two o

205 tions and factors associated with consistent exacerbations over time.

206 ty was associated with a higher frequency of exacerbations (P < 0.0001) but was not independently ass

207 s of NET complexes in patients with frequent exacerbations (P = .002).

208 Sputum elastase activity increased at exacerbations (P = 0.001) and was responsive to treatmen

209 but no evidence of an association with COPD exacerbations (p=0.35) or the other indices of COPD seve

210 aled a significantly different between-group exacerbation pattern that was consistent with the primar

211 in participants with two or more respiratory exacerbations per year than in those with zero exacerbat

212 virus (RSV) activity with risk of pulmonary exacerbation (PEx) in persons with CF in the United Stat

213 d, symptomatic COPD had an increased risk of exacerbations, pneumonia, and death.

214 proportional hazard models to assess risk of exacerbations, pneumonia, deaths due to respiratory caus

215 otype with implications for the targeting of exacerbation prevention strategies.

216 in the past year: none, few (one to two), or exacerbation prone (>/=3).

217 41%) had no exacerbations and 173 (24%) were exacerbation prone in the prior year.

218 thma therapies, but the clinical features of exacerbation-prone asthma (EPA) remain incompletely defi

219 Our results indicate that exacerbation-prone asthma may be a separate asthma endot

220 pic: (n = 153); "Late-onset" (n = 105); and "Exacerbation-prone asthma" (n = 13).

221 chodilator responsiveness also discriminated exacerbation proneness from asthma severity.

222 ative Omalizumab or Step-Up Therapy for Fall Exacerbations (PROSE) study.

223 ed time to first exacerbation and subsequent exacerbation, quality of life, and change in weight.

224 lated with bronchial neutrophils (r = 0.54), exacerbation rate (r = 0.41), and FEV1 (r = -0.46).

225 that long-acting bronchodilators can reduce exacerbation rate and/or severity, and others have shown

226 significantly associated with a lower asthma exacerbation rate during the outcome period and correlat

227 The annualised pulmonary exacerbation rate in patients continuing treatment throu

228 nistered every 4 weeks resulted in an annual exacerbation rate that was 55% lower than the rate with

229 nistered every 8 weeks resulted in an annual exacerbation rate that was 70% lower than the rate with

230 s) to severe asthmatics (SAs) in relation to exacerbation rate.

231 primary endpoint was moderate-to-severe COPD exacerbation rate.

232 te ratio, 1.6; 95% CI, 1.1-2.3; P = .03) and exacerbations (rate ratio, 1.9; 95% CI, 1.1-3.3; P = .02

233 To identify distinct trajectories of severe exacerbation rates among "problematic asthma" patients a

234 Thus, exacerbation rates in the respective tezepelumab groups

235 Severe exacerbation rates over five years for 177 "problematic

236 Moderate-to-severe exacerbation rates were 0.46 (95% CI 0.41-0.51) for fixe

237 high fractional exhaled nitric oxide levels, exacerbation rates, and oral corticosteroid use, whereas

238 Annual asthma exacerbation rates, lung function, symptoms, and safety

239 been associated with increased frequency of exacerbations, reduced lung function, and corticosteroid

240 st MS patients experience periods of symptom exacerbation (relapses) followed by periods of partial r

241 mechanisms associated with steroid-resistant exacerbations remain largely unknown.

242 the context, yet their involvement in asthma exacerbations remains unexplored.

243 D supplementation reduced the rate of asthma exacerbation requiring treatment with systemic corticost

244 the 16-week ICS dose-stable phase, rates of exacerbations requiring >/=3 days of systemic corticoste

245 Exacerbations requiring corticosteroids treatment were m

246 The primary end points were the rate of exacerbations requiring hospitalization and the rate of

247 Mepolizumab approximately halved exacerbations requiring hospitalization and/or emergency

248 ns requiring hospitalization and the rate of exacerbations requiring hospitalization/emergency room v

249 For budesonide versus placebo, severe exacerbations requiring oral or systemic corticosteroids

250 ophilic asthma and a history of at least two exacerbations requiring treatment in the previous 12 mon

251 D supplementation reduces the rate of asthma exacerbations requiring treatment with systemic corticos

252 Present treatment strategies to stratify exacerbation risk in patients with chronic obstructive p

253 Identify Undiagnosed Respiratory Disease and Exacerbation Risk), was used to assess exposure, breathi

254 nced by improved symptom control and reduced exacerbation risk.

255 Women with asthma exacerbation(s) had larger gestational weight gain (GWG)

256 RVs were detected in 97 (57%) of 171 exacerbation samples and 2,150 (36%) of 5,959 nonexacerb

257 with anti-IL-33 or dexamethasone diminished exacerbation severity, and anti-IL-33, but not dexametha

258 ss, and MMP-1 activation are associated with exacerbation severity.

259 Although glucocorticoids are used to manage exacerbations, some patients respond to them poorly.

260 malizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examined children with allergic

261 copyronium vs Fluticasone Salmeterol on COPD Exacerbations) study, which compared once-daily long-act

262 nasal mucosa of neutrophilic asthma prone to exacerbation, suggesting a pathogenic role of IL-17F in

263 th a lower annual rate of moderate or severe exacerbations than placebo among patients with COPD and

264 lower rates of clinically significant asthma exacerbations than those who received placebo, independe

265 ong patients with CF was able to detect more exacerbations than usual care, but this did not result i

266 ol of chronic asthma and reduction in asthma exacerbations, the major cause of asthma mortality.

267 emergency hospital attendance with an asthma exacerbation to receive mite-impermeable (active group)

268 FF/VI also reduced the rate of exacerbations treated with corticosteroids alone or with

269 Subgroup analyses of the rate of asthma exacerbations treated with systemic corticosteroids reve

270 e progression, established disease, or viral exacerbation using a preclinical model of chronic asthma

271 ether effects of vitamin D on risk of asthma exacerbation varied according to baseline 25-hydroxyvita

272 The rate of pulmonary exacerbation was 35% lower in the tezacaftor-ivacaftor g

273 Obstructive Lung Disease stage 1, where each exacerbation was associated with an additional 23 ml/yr

274 An exacerbation was defined as a burst of systemic corticos

275 e groups in the risk of prednisolone use for exacerbation was found (hazard ratio, 0.82; 95% CI, 0.58

276 The exacerbation was preceded at 14 h after virus exposure b

277 icipants to determine if treatment for acute exacerbation was required.

278 , the mean annual rate of moderate or severe exacerbations was 1.19 per year in the 100-mg mepolizuma

279 l rate of emergency hospital attendance with exacerbations was 27% lower in the active group than in

280 bo, on the annual rate of moderate or severe exacerbations was found among patients with higher blood

281 hmatic patients with stable disease or acute exacerbations was further studied to determine the prese

282 tion period, the occurrence of severe asthma exacerbations was investigated.

283 t pattern (both years with and without acute exacerbations) was common (456 [41%] of the group), part

284 ignificantly reduces the incidence of asthma exacerbations, was also effective as an oral glucocortic

285 In subjects with COPD, exacerbations were associated with excess FEV1 decline,

286 Exacerbations were modeled for biomarker associations wi

287 for RVs, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during

288 Myasthenia gravis exacerbations were reported by six (10%) patients in the

289 c airway disease (AAD) and virus-induced AAD exacerbations were used to dissect pDC function in vivo

290 worsened during cough episodes and pulmonary exacerbations, whereas similar symptoms in healthy child

291 sis (CF) experience frequent acute pulmonary exacerbations, which lead to decreased lung function and

292 ncytial virus (RSV) infection induces asthma exacerbations, which leads to worsening of clinical symp

293 COPD who had a history of moderate or severe exacerbations while taking inhaled glucocorticoid-based

294 e interval, 2-44; P = 0.03), and each severe exacerbation with an additional 87 ml/yr decline (95% co

295 rflow obstruction experienced a reduction in exacerbations with FF/VI compared with placebo, irrespec

296 ically significant reductions in the rate of exacerbations with mepolizumab treatment.

297 in a separate trial designed to prevent fall exacerbations with omalizumab therapy.

298 reviously unsuspected role of pDCs in asthma exacerbations with potential diagnostic and prognostic i

299 viruses (HRVs) are a major trigger of asthma exacerbations, with the bronchial epithelium being the m

300 ding pathogens in asthma onset, severity and exacerbation, yet with the exception of antibiotics, few